Compare Equitable Holdings Inc. Common Stock (EQH) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equitable Holdings Inc. Common Stock vs State Street SPDR S&P Biotech ETF — how do they compare? Equitable Holdings Inc. Common Stock trades at $52.77 (market cap $14.49B), while State Street SPDR S&P Biotech ETF trades at $147.13 (market cap $10.27B). The key difference: Equitable Holdings Inc. Common Stock is the larger of the two by market cap, and Equitable Holdings Inc. Common Stock pays a 2.15% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Equitable Holdings Inc. Common Stock for 0 Days and State Street SPDR S&P Biotech ETF for 39 Days on average.
| EQH | XBI | |
|---|---|---|
Market Cap | $14.49B | $10.27B |
Volume | 2,405,401 | 9,751,587 |
Sector | Financials | Broad Market / Factor |
52-Week High | $54.50 | $169.55 |
52-Week Low | $35.34 | $107.32 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $5.54B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equitable Holdings (EQH) trades at $53.12, down 0.75% on the day, with strong analyst support (95% buy ratings) and a $64.71 consensus price target suggesting 22% upside. Recent quarterly earnings have consistently beaten expectations, though the company reported a net loss of $1.38B for 2025. The planned merger with Corebridge and expansion into fee-based businesses are key growth drivers, while high debt-to-asset ratio of 2.07 presents financial risk.
EQH shows mixed fundamentals with positive earnings momentum but negative profitability metrics. The stock offers significant upside potential based on analyst targets, supported by strategic initiatives and dividend appeal. Key risks include execution of the Corebridge merger, persistent net losses, and high leverage. Investors should weigh strong analyst conviction against fundamental weaknesses.
XBI trades at $146.8, down 3.04% today, with a bearish technical signal driven by selling pressure in moving averages. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from M&A activity and positive clinical catalysts. Recent news highlights sector optimism from cancer vaccine breakthroughs and improved capital access, though the ETF carries higher volatility than diversified healthcare funds.
Outlook remains mixed with neutral analyst consensus but positive sector catalysts. Opportunities include biotech innovation and M&A potential, while risks involve high volatility, regulatory uncertainty, and expense ratios above broader healthcare ETFs. Investors should weigh targeted biotech exposure against sector-wide stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Equitable Holdings Inc. Common Stock
Equitable Holdings, Inc. is a financial services holding company operating through Equitable, AllianceBernstein, and Equitable Advisors. It provides retirement and protection products, asset and wealth management services, and financial planning through a network of registered financial professionals.
Read more on EQH →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
